newsfilter
← Latest News
Business Wire·

FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer

  • The FDA has approved WILSERDLY (giredestrant) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy.
  • WILSERDLY is the first next-generation all-oral SERD combination to significantly outperform standard endocrine therapy plus everolimus in a head-to-head Phase III trial (evERA) for patients post-CDK4/6 inhibitor treatment.
  • In ESR1-mutated patients, the WILSERDLY and everolimus combination delayed disease progression or death by 62% compared to standard therapy, with a stratified hazard ratio of 0.38.
  • Up to 40% of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations, which are a primary driver of resistance to hormone therapy.
  • Genentech has submitted a New Drug Application for WILSERDLY in the adjuvant setting for early-stage breast cancer, with an FDA decision expected by November 30, 2026.
  • If the adjuvant indication is approved, WILSERDLY will become the first SERD approved for both adjuvant and advanced ER-positive breast cancer.
  • The drug is expected to be available in the U.S. in the coming weeks, with patient access support including a co-pay assistance program potentially reducing costs to $0 for eligible commercial patients.
  • WILSERDLY is an oral selective estrogen receptor degrader designed to block estrogen binding, degrade the ER protein, and synergize with everolimus to target the PI3K/AKT/mTOR signaling pathway.
  • Common side effects include decreased blood cell counts, elevated liver enzymes, mouth sores, diarrhea, fatigue, and potential bradycardia requiring heart rate monitoring.
  • Patients are advised to avoid grapefruit products during treatment and use effective non-hormonal contraception due to potential fertility risks.
  • The FDA-authorized test is required to confirm the presence of ESR1 mutations before initiating WILSERDLY therapy.